Abstract: An information processing apparatus (10) includes a time and space information acquisition unit (110) that acquires high-risk time and space information indicating a spatial region with an increased possibility of an accident occurring or of a crime being committed and a corresponding time slot, a possible surveillance target acquisition unit (120) that identifies a video to be analyzed from among a plurality of videos generated by capturing an image of each of a plurality of places, on the basis of the high-risk time and space information, and analyzes the identified video to acquire information of a possible surveillance target, and a target time and space identification unit (130) that identifies at least one of a spatial region where surveillance is to be conducted which is at least a portion of the spatial region or a time slot when surveillance is to be conducted, from among the spatial region and the time slot indicated by the high-risk time and space information, on the basis of the information of the

Abstract: An information processing apparatus (10) includes a time and space information acquisition unit (110) that acquires high-risk time and space information indicating a spatial region with an increased possibility of an accident occurring or of a crime being committed and a corresponding time slot, a possible surveillance target acquisition unit (120) that identifies a video to be analyzed from among a plurality of videos generated by capturing an image of each of a plurality of places, on the basis of the high-risk time and space information, and analyzes the identified video to acquire information of a possible surveillance target, and a target time and space identification unit (130) that identifies at least one of a spatial region where surveillance is to be conducted which is at least a portion of the spatial region or a time slot when surveillance is to be conducted, from among the spatial region and the time slot indicated by the high-risk time and space information, on the basis of the information of the

Abstract: A diagnostic agent for pancreatic exocrine function comprising a dipeptide represented by the following formula (I): X1—R1—Y1??(I) or a pharmaceutically acceptable salt thereof, wherein X1 is a protecting group, R1 is a phenylalanine, glutamine, valine, tyrosine, methionine, serine or threonine residue, and Y1 is a 13C-labeled alanine molecule optionally having a protecting group.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U—13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13C- or 14C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13C- or 14C-labeled.

Abstract: The present invention provides a diagnostic agent for evaluating gastric emptying function and/or small intestinal absorptive capacity which imposes less burden to subjects and which is capable of obtaining objective test results in a short period of time. A diagnostic agent for evaluating gastric emptying function and/or small intestinal absorptive capacity, comprising succinic acid labeled with a stable isotope 13C or a pharmaceutically acceptable salt thereof.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: A diagnostic reagent for use in the evaluation of a pharmacological effect of a medicine containing a pharmaceutical agent including an enzyme, an enzyme inhibitor or a receptor ligand or a prodrug of the pharmaceutical agent is provided. Further, a method of screening pharmaceutical agents each comprising an enzyme, an enzyme inhibitor or a receptor ligand and/or prodrugs of the pharmaceutical agents is provided.

Abstract: A diagnostic agent for pancreatic exocrine function comprising a dipeptide represented by the following formula (I): X1—R113 Y1??(I) or a pharmaceutically acceptable salt thereof, wherein X1 is a protecting group, R1 is a phenylalanine, glutamine, valine, tyrosine, methionine, serine or threonine residue, and Y1 is a 13C-labeled alanine molecule optionally having a protecting group.

Abstract: A diagnostic agent for pancreatic exocrine function comprising a dipeptide represented by the following formula (I): X1—R1—Y1??(I) or a pharmaceutically acceptable salt thereof, wherein X1 is a protecting group, R1 is a phenylalanine, glutamine, valine, tyrosine, methionine, serine or threonine residue, and Y1 is a 13C-labeled alanine molecule optionally having a protecting group.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: A diagnostic agent for pancreatic exocrine function comprising a dipeptide represented by the following formula (I): X1—R1—Y‘??(I) or a pharmaceutically acceptable salt thereof, wherein X1 is a protecting group, R1 is a phenylalanine, glutamine, valine, tyrosine, methionine, serine or threonine residue, and Y1 is a 13C-labeled alanine molecule optionally having a protecting group.

Abstract: A diagnostic reagent for use in the evaluation of a pharmacological effect of a medicine containing a pharmaceutical agent including an enzyme, an enzyme inhibitor or a receptor ligand or a prodrug of the pharmaceutical agent; and a method of screening pharmaceutical agents each comprising an enzyme, an enzyme inhibitor or a receptor ligand and/or prodrugs of the pharmaceutical agents for one or ones having high medicative efficacy and/or a small side effect are provided.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: A composition for rouge for lip of the present invention is a composition for rouge for lip containing a volatile oil content, a water-repellent polymer soluble to the volatile oil content, powder, and a nonvolatile oil content having a compatibility with the volatile oil content, wherein the powder contained in 1 g of the composition has a total surface arm of 1 to 25 m.sup.2.According to the composition for rouge for lip of the present invention, a composition for rouge for lip in which the secondary adhesion is improved and feel of use is excellent can be obtained.

Abstract: The present invention relates to a diagnostic agent for diabetes, which comprises glucose labelled with 13C at a specific position, or pyruvic acid labelled with 13C at least one specific position. According to the present invention, there is provided a diagnostic agent for diabetes which can be used safely without side effects to give accurate results immediately with less physical pains on the subject. The present diagnostic agent for diabetes can distinguish between healthy persons and patients with diabetes even under the circumstances where the patients are easily missed, and further it can determine the type of diabetes (insulin-dependent type or insulin-independent type).